Cara Therapeutics reported $-30745000 in Net Income for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Acadia Pharmaceuticals ACAD:US $ -43.87M 22.58M
Acelrx Pharmaceuticals ACRX:US $ -9.85M 0.9M
Aerie Pharmaceuticals AERI:US $ -38.69M 3.28M
Antares Pharma ATRS:US $ 4.42M 0.63M
Arena Pharmaceuticals ARNA:US $ -146.1M 27.68M
Cara Therapeutics CARA:US $ -30745000 7.44M
Chugai Pharma 4519:JP Y 86017M 15291M
Endo International Ordinary Shares ENDP:US $ -15.5M 57.02M
Halozyme Therapeutics HALO:US $ 91.46M 63.56M
Horizon Pharma HZNP:US $ 158.12M 281.47M
JAZZ PHA JAZZ:US $ -363.32M 485.15M
Johnson & Johnson JNJ:US $ 3667M 2611M
Neurocrine Biosciences NBIX:US $ 42.3M 10.2M
Pacira Pharmaceuticals PCRX:US $ 19.08M 8.71M
Pain Therapeutics PTIE:US $ -5.12M 1.6M
Pfizer PFE:US $ 5564M 686M
Redhill Biopharma RDHL:US $ -29.12M 6.26M
Revance Therapeutics RVNC:US $ -72.2M 0.56M
Supernus Pharmaceuticals SUPN:US $ 23.73M 18.03M
Teva Pharmaceutical Industries TEVA:US $ 207M 129M
Vanda Pharmaceuticals VNDA:US $ 9.65M 1M